Objective T o determine the contribution of herpes simplex virus (HSV) to serious neurological disease. Setting and patients A 3-year prospective survey of children aged 2-23 months in Britain and Ireland. Results 19 children had HSV central nervous system (CNS) infection; 13 aged 2-11 months had focal neuroimaging abnormalities and 11 long-term neurological sequelae. Of six aged 12-35 months, one had abnormal neuroimaging and three longterm neurological sequelae. 17 of the 19 had serious neurological disease. HSV CNS infection accounted for 23% of serious neurological disease in children aged 2-11 months and 4.5% in older children. Conclusions The incidence of HSV-induced serious neurological disease in the UK was estimated at 1 in 64 000/year in younger children and 1 in 230 000 in older children. HSV CNS infection has clinical effects ranging from frank encephalitis to severe illness with fever and convulsions to milder disease lacking encephalopathy.
INTRODUCTION
H erpes simplex encephalitis (HSE) is the most common cause of sporadic encephalitis and without treatment 70% of patients die. Our knowledge of HSE relies on two clinical trials of antiviral drugs from the 1980s. Since then substantial changes in diagnostic methods, including PCR to test cerebrospinal fl uid (CSF) for herpes simplex virus (HSV) DNA together with the use of aciclovir, have improved survival. However, the spectrum of clinical manifestations and longterm outcome need to be better defi ned so as to improve management and thereby decrease the still considerable morbidity and mortality associated with this devastating condition.
A prospective survey of children aged 2-23 months in Britain and Ireland with serious neurological disease showed for the fi rst time that human herpesvirus-6 and -7 contributed signifi cantly to this illness. 1 Data collected included information on other pathogens, including HSV, and thus its contribution to the burden of disease could be assessed. The present paper reports the results obtained.
METHODS

Patients Case ascertainment
Between October 1998 and September 2001 paediatricians were requested by the British Paediatric Surveillance Unit to report the cases of all children 2-35 months old with serious neurological disease. 1 Neonates were excluded from the survey to avoid inclusion of inherited and mechanical neurological damage which often presents before 2 months of age. Details of each child's neurological illness were collected using a short standard questionnaire. A further brief questionnaire was sent after at least a year to check long-term outcome, that is, whether the child had recovered or suffered developmental delay, persisting neurological defi cit or convulsions. An additional questionnaire was sent to the referring hospital's microbiology laboratory to confi rm the microbiological results at the time of the child's illness. Each questionnaire was scrutinised by a physician (KNW) to determine whether the details fi tted the case defi nition (see below). Diffi cult cases were referred to one or more paediatricians (AO, CMV, EMR) for a fi nal decision. The database of all reported disease episodes, regardless of whether or not they met the case defi nition, was re-examined by KNW for individuals with HSV central nervous system (CNS) infection.
Defi nitions Fever
Fever was defi ned as a temperature ≥37.5°C. to IgG or IgM, within 2 weeks of onset of serious neurological disease.
Ethics approval
Ethics approval was given by the Public Health Laboratory Service Ethics Committee, London.
RESULTS
Cases of serious neurological disease
Of the 267 episodes of disease reported, 19 cases of HSV CNS infection ( table 1 ) and 163 cases of serious neurological disease were identifi ed; 52 of the latter were in children aged 2-11 months and 111 in children aged 12-35 months.
The clinical features, neuroimaging results and long-term outcome of the 19 cases are given in table 2 . Every case presented with convulsions (partial in 12/19) accompanied by fever in all but one instance. Focal neuroimaging abnormalities were noted in all children aged <11 months (temporal lobes in nine, frontal lobes in three and parietal lobes in seven) but in only one of the older children. T here were no deaths, but 11 of the 13 children aged 2-11 months and three of the six older children had long-term neurological sequelae. The most common sequela was developmental delay, but other persisting defi cits included hemiparesis, quadriparesis and visual problems. Eight children had epilepsy.
Two patients (nos. 12 and 15) with HSV CNS infection did not meet our case defi nition of serious neurological disease.
The remaining 17 (11 encephalitis, six severe illness with fever and convulsions) accounted for 23% (12/52) of episodes of serious neurological disease in children <1 year old and 4.5% (5/111) in the older children. Because all 17 cases were in British children, we could estimate the incidence of serious neurological disease due to HSV CNS infection in the UK as 1 in 64 000/year in children aged 2-11 months and 1 in 230 000/ year in children aged 12-35 months. In 1998-2001 there were 2.1 million children in the fi rst year of life and 4.1 million in the second and third years (National Statistics Offi ce website: http://www.statistics.gov.uk/popest ).
DISCUSSION
T his paper reports data on the incidence, spectrum of clinical presentation and long-term outcome of virologically confi rmed HSV CNS infection in young children throughout the British Isles. So that milder cases would be included, the defi nition of HSV CNS infection covered more than just serious neurological disease, which in turn comprised not only encephalitis but also severe illness with fever and convulsions.
Thus only 58% of the children with HSV CNS infection in the survey had an illness that fi tted our strict defi nition of encephalitis as the remainder did not fulfi l the criterion of encephalopathy for ≥24 h. Such atypical forms of HSV CNS infection have been previously reported 2 3 and together with our fi ndings show that HSV is responsible for more than clearcut encephalitis in young children.
Cases may have been missed in our survey because HSV DNA or pleocytosis may not be found in CSF soon after disease onset. Likewise, aciclovir treatment may result in the absence of CSF HSV DNA and delay antibody seroconversion. Indeed, nowadays CSF is rarely tested for intrathecal HSV antibody 4 and this was certainly our experience. Finally, the declining use of HSV serum antibody tests together with a decrease in the use of lumbar puncture in paediatric practice may have affected detection. 5 However, it seems that in fact few cases were missed. fi t well with our fi nding of postnatal HSV CNS infection if allowance is made for exclusion of neonates. HSE classically presents as an acute illness characterised by fever and encephalopathy together with behavioural disturbances and/or motor defi cits and/or convulsions. No sign is pathognomic, but it is noteworthy that in our children <3 years old, convulsions (generalised or focal) were present in every case. Similarly, two studies of postnatal HSE 2 7 report a predominance of convulsions in children aged <3 years as compared to older children who show a wider range of presentations.
Neuroradiology of postnatal HSE typically reveals focal haemorrhagic lesions localised to the medial temporal lobes, the insula and the orbital region of the frontal lobes of the brain. However, in our series the parietal lobes were frequently affected, confi rming previous fi ndings that in young children extra-temporal regions of the brain are often involved. 2 3 8 HSE outcome is diffi cult to predict early on and particularly in very young children in whom subtle defects may appear later; it is therefore important that almost all of our cases were followed up at least a year after presentation. Long-term sequelae were reported in many of the children. Adverse outcome was age-related and CT refl ected this as abnormalities were described in all the younger children but in none aged >11 months. Likewise, high numbers of red cells in the CSF, refl ecting haemorrhagic necrosis in the CNS, were confi ned to the younger age group. Of other recent studies of the long-term outcome of HSV CNS infection, that is, at least 6 months after onset, 2 9 10 one 10 reported that patients 3-35 months old were more likely to be severely disabled than older children. Our series further suggests that those <1 year old were at highest risk. Poor neurological outcome is associated with delayed initiation of aciclovir therapy and/or shorter courses of the drug but, although all children received aciclovir, the confounding effects of inadequate treatment could not be addressed as this information was not collected by us nor in the study of Ito et al . 10 The infl uence of age of onset in relation to severity of long-term outcome requires prospective study taking into account the role of inadequate aciclovir therapy.
In conclusion, this survey documents the incidence of HSV-induced serious neurological disease in young children in Britain and emphasises that there are various presentations ranging from frank encephalitis to severe illness with fever and convulsions, and even a milder form lacking lengthy encephalopathy. Disease was commoner in children aged 2-11 months than in older children, and neurological sequelae and consequent severe disabilities showed the same trend. HSV CNS infection must always be considered in children presenting with convulsions even when apyrexial, without encephalopathy and with normal CT fi ndings.
